Premium
Anti‐inflammatory activity of lanoconazole, a topical antifungal agent
Author(s) -
Uratsuji Hideya,
Nakamura Aki,
Yamada Yoshihito,
Hashimoto Kei,
Matsumoto Tatsumi,
Ikeda Fumiaki,
Ishii Ritsuko
Publication year - 2015
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/myc.12297
Subject(s) - peripheral blood mononuclear cell , in vivo , contact dermatitis , pharmacology , antifungal , inflammation , in vitro , chemistry , irritant contact dermatitis , interleukin , immunology , cytokine , medicine , dermatology , allergy , biochemistry , biology , microbiology and biotechnology
Summary Topical antifungal agents which have anti‐inflammatory effects have the potential to provide additional clinical benefits. Therefore, an anti‐inflammatory activity of lanoconazole ( LCZ ), a topical antifungal agent, was investigated against in vitro and in vivo models of inflammation. The release of interleukin‐8 ( IL ‐8) from human epidermal keratinocytes stimulated by the addition of 100 μg ml −1 β‐glucan of S accharomyces cerevisiae was significantly inhibited by LCZ at the concentration of 10 −5 mol l −1 . The release of interferon‐γ and IL ‐2 from human peripheral blood mononuclear cells stimulated by the addition of 30 and 100 μg ml −1 phytohemagglutinin was significantly inhibited by LCZ at the concentrations of 10 −7 and 10 −6 mol l −1 , respectively. The increase in the ear thickness induced by topical application of 0.01% 12‐ O ‐tetradecanoyl phorbol‐13‐acetate and 1% 2,4,6‐trinitrochlorobenzene ( TNCB ) after sensitisation with 3% TNCB were established as the mouse models of irritant and contact dermatitis, respectively. Application of 1% and 3% LCZ showed a significant anti‐inflammatory activity against both the irritant and contact dermatitis models. These findings suggest that LCZ possesses an anti‐inflammatory activity, which may be partially helpful in the treatment of dermatomycoses.